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Background/aim: Erythema nodosum (EN) is an inflammatory disorder of subcutaneous tissue. Although etiopathogenesis of the
disease is unknown, many predisposing factors such as infections, systemic disease, and drugs have been identified. Neutrophil to
lymphocyte ratio (NLR) has been shown to be a novel inflammatory marker in many dermatological diseases. The aim of our study is
to investigate NLR in EN patients and evaluate its relation to the underlying cause of the disease.
Materials and methods: Between 2014 and 2018, clinical and laboratory data of 395 patients diagnosed with EN and 395 controls were
extracted from patient files. EN patients were grouped as idiopathic EN and secondary EN (EN with an identified underlying cause).
Clinical and laboratory characteristics of the two groups were compared.
Results: NLR was elevated in EN patients compared to controls (median of 2.38 vs. 1.55, P < 0.001). Among EN patients, NLR was also
elevated in patients with secondary EN. In multivariate logistic regression model NLR (> 2.11), RDW-CV (> 13.65), and CRP (> 5.5)
were identified as risk factors for secondary EN (relative risks were 17.16, 2.69, and 2, respectively).
Conclusion: Elevated NLR (> 2.11) may be used as a parameter to discriminate secondary EN from idiopathic EN.
Key words: Erythema nodosum, neutrophil to lymphocyte ratio, etiological factors

1. Introduction
Erythema nodosum (EN) is an inflammatory disorder
of subcutaneous tissue characterized by erythematous,
tender subcutaneous nodules predominantly affecting
lower extremities. The pathogenesis of EN is not well
understood. Hypersensitivity reaction against an unknown
antigen is the main theory, but some authors suggested
that neutrophils also contribute to EN pathogenesis (1,2).
Kunz et al. showed that reactivated neutrophils increased
in patients with EN and the ratio of reactive oxygen
intermediates producing polymorphonuclear neutrophils
correlate with disease severity (3).
Although one third of EN is idiopathic, more than
half of the patients have secondary EN with etiologic
factors such as infections, systemic disease, and drugs
that support the hypersensitivity reaction hypothesis in
pathogenesis (4–6). Identifying and eliminating these
etiological factors is the first step of EN treatment and
may limit the recurrences of EN (1,7–9). Medical history
and physical examination easily identify known infections
and systemic diseases, but in patients with inconclusive
history additional laboratory tests are needed. Although

some demographic, clinical, and laboratory features
such as advanced age, atypical localization of the lesions,
increased ESR and CRP are more common in patients
with secondary EN, no laboratory parameter with high
sensitivity and specificity was identified to recognize EN
patients with a possible precipitating factor.
Neutrophil to lymphocyte ratio (NLR) is a novel
inflammatory marker identified in cardiac and
inflammatory disorders (10–13). NLR increases in
inflammatory diseases, correlates with disease severity
and conventional inflammatory markers, and may predict
response to treatment and survival (14–20). The aim of
this study is to evaluate NLR in EN patients, investigate
its relationship with etiological factors and its value as a
predictor of secondary EN.
2. Materials and methods
2.1. Study design and data source
We retrospectively analyzed patients diagnosed with
EN from January 2014 to January 2018 in a single
tertiary referral center using International Classification
of Diseases, Ninth Revision codes. A dermatologist
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reviewed patient charts from a local hospital database
and dermatology department’s archive of 737 patients.
After elimination of unfit records (Figure 1), 395 patients
diagnosed with EN were included in this study. The study
was approved by the Ethics Committee of Ankara Numune
Training and Research Hospital (E–18–1814).
2.2. Study population
Demographic, clinical, and laboratory data including
age, sex, cause of EN, presence of a previous EN attack,
complete blood count with differential, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and
skin biopsy results were retrieved from patient records.
All patients included in the study were tested for upper
respiratory tract infection (URTI) using antistreptolysin-O
(ASO) and throat culture, for urinary tract infection (UTI)
using complete urinary analysis and urine culture, and
for rheumatologic diseases using antinuclear antibodies,
extractable nuclear antigen, rheumatoid factor, anti-ds
DNA, antigliadin, antitransglutaminase antibody, and
antiendomysium. Screening for other etiological factors
was performed based on patient history. Drug use within
3 weeks prior to EN was recorded. Antibiotic use was not
included in drug induced EN but classified within infection
related EN. EN patients were divided into two major
groups as idiopathic EN and secondary EN according to

the presence of an etiological factor. Secondary EN patients
were further divided into two groups as (i) secondary EN
patients with a precipitating factor either initially known
at admission due to a prior diagnosis or recognized in an
overt symptomatic presentation, and (ii) those diagnosed
after detailed laboratory workup.
Same number (n = 395) of age and sex matched
noninflammatory, noninfective dermatosis patients from
the same period were included in the study as control
group.
2.3. Laboratory data
In all cases, complete blood count with differential,
ESR (millimeters (mm)/hour), and CRP (mg/dL) were
recorded from patient files. NLR, monocyte-lymphocyte
ratio (MLR), and platelet-lymphocyte ratio (PLR) were
calculated by dividing the absolute neutrophil, monocytes,
and platelet counts by the absolute lymphocyte counts,
respectively: NLR = neutrophils (10³ µL)/lymphocytes
(10³ µL), MLR = monocytes (10³ µL)/lymphocytes (10³
µL), PLR = platelets (10³ µL)/lymphocytes (10³ µL).
3.4. Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics for Windows, Version 21.0 (IBM Corp., NY,
USA). Quantitative and qualitative variables were analyzed
using Chi-square test and Mann-Whitney U test. Variables

ICD 9search for EN between
2014 -2018
n=737
Readmisions of the same
patients n= 168
Patients ’ medical
records were reviwed
n=569

EN patients included in the
study n= 395

İdiopathic EN n=137

Excluded patients n=174
• Patients <18 years old n=22
• Panniculitisduring pregnancy n= 9
• Patients with inadequate
laboratory data n=69
• Diagnosis of EN wasn’t confirmed
clinicallyor histopathologically by
dermatologist n=73

Secondary EN (EN with
identified precipitating
factors) n=258

Figure 1. Flowchart summarizing patient inclusion and exclusion processes.
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with a P value < 0.2 in univariate analysis were further
entered into logistic regression analysis to determine the
independent predictors of secondary EN. Spearman’s
correlation test was used for correlation analysis of
quantitative variables and a P value < 0.05 was considered
as statistically significant.
3. Results
3.1. Patient characteristics
Eighty percent of the patients were female (n = 316) and
20% were male (n = 79). The median age of patients was 39
(IQR: 29–51). The main characteristics of EN patients are
summarized in Table 1. Among the EN patients, 34.7% (n =
137) were idiopathic and 65.3% (n = 258) had a secondary
factor that may cause, precipitate, or aggravate EN. Among
258 secondary EN patients, 56.6% (n = 146) had infection,
33.7% (n = 87) had systemic diseases, 6.6% (n = 17) had
drug use, and 3.1% (n = 8) had malignancy as a cause.
Infections, systemic diseases, and drugs are listed in detail
in Table 2. The cause of secondary EN was initially known
in 40.3% (n = 104) of the patients. After routine screening,
56.8% of patients with infection and 81.6% of patients
with systemic diseases were identified (Table 3). All of the
malignancies and drugs reported by the patients were listed
as participating factors in medical histories.
Recurrent EN was observed in 16.2% of the patients,
while in 83.8% of the patients no previous history of EN
was noted. Age, percentage of secondary EN, and RDV-CV
levels were higher in patients with recurrent EN compared
to nonrecurring EN (P = 0.044, 0.001, and 0.042). Although
CRP, NLR, and MLR levels were also elevated, the difference
was not statistically significant (P = 0.054, 0.15, and 0.19,
respectively). Clinical and laboratory features of recurrent
and nonrecurrent EN are summarized in Table 4.

Table 1. Characteristics of EN patients.
Characteristic

N (%)

Age (years)

39 (29–51) *

Sex, male

79 (20)

EN type
Idiopathic EN
Secondary EN

137 (34.7)
258 (65.3)

Recurrence
Present
Absent

64 (16.2)
331 (83.8)

Diagnosis
Histopathological
Clinical

78 (19.7)
352 (80.3)

* Median (IQR), EN: erythema nodosum.
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Table 2. Causes of secondary EN.
Cause

N (%)

Infection
URTI
UTI
Skin
LRTI
GIS

146 (56.6)
82
48
5
3
3

Systemic diseases
Rheumatologic
Pulmonary
Intestinal

87 (33.7)
71
10
6

Drug
OCs
NSAIDs

17 (6.6)
12
5

Malignancy
Hematological malignancies
Endometrial cancer
Breast cancer

8 (3.1)
5
2
1

Total

258 (100)

EN: erythema nodosum, URTI: upper respiratory tract infection;
UTI: urinary tract infection, LRTI: lower respiratory tract
infection, GIS: gastrointestinal system, NSAIDs: nonsteroidal
antiinflammatory drugs, OCs: oral contraceptives.

In 352 patients EN was diagnosed clinically,
and in 78 patients clinical diagnosis was confirmed
histopathologically. Both clinically and histopathologically
diagnosed EN patients were similar in age and sex (P = 0.39
and P = 0.68), but secondary EN and recurrence was more
frequent in histopathologically diagnosed EN (both P <
0.01).
3.2. Laboratory data
Laboratory features of EN patients compared to control
group are listed in Table 5 and laboratory features of
secondary EN patients compared to idiopathic EN are listed
in Table 6. NLR was higher in EN patients compared to
control group (P < 0.001). Median NLR was 2.38 (IQR 1.73–
3.58) in patients and 1.55 (IQR 1.23–1.8) in controls (Figure
2). NLR of both secondary and idiopathic EN patients was
significantly higher than control group (P < 0.001 and P =
0.003, respectively) and NLR of secondary EN patients was
higher than idiopathic EN (P < 0.001) (Figure 3).
Similar to NLR, both MLR and PLR increased
significantly (all P < 0.001) in EN compared to control
group in secondary EN compared to idiopathic EN.
We also showed NLR, MLR, and PLR to be correlated
with each other and with other conventional inflammatory
markers (Table 7).
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Table 3. Etiological factors in secondary EN patients by time of discovery.
Cause

Known at
admission N (%)

Diagnosed after
work-up N (%)

Total

Infection
UTI
URTI
Other

63 (43.2)
2
48
13

83 (56.8)
46
34
3

146 (56.6)

Systemic diseases
Rheumatologic
Pulmonary
Other

16 (18.4)
12
1
3

71 (81.6)
59
9
3

87 (33.7)

Drug
OCs
NSAIDs

17 (100)
12
5

-

17 (6.6)

Malignancy
Hematological malignancies
Endometrial cancer
Breast cancer

8 (100)
5
2
1

-

8 (3.1)

Total

104 (40.3)

154 (59.7)

258 (100)

URTI: upper respiratory tract infection, UTI: urinary tract infection, LRTI: lower respiratory tract
infection, GIS: gastrointestinal system, NSAIDs: nonsteroidal antiinflammatory drugs, OCs: oral
contraceptives.
Table 4. Clinical and laboratory features of recurrent and nonrecurrent EN.
Nonrecurrent EN

Recurrent EN

P

Age median (IQR)

38 (29–50)

45 (34–51)

0.044

Sex (male/female)

68/263

11/53

0.54

Cause (idiopathic/secondary)

127/204

10/54

< 0.001

Neutrophil

8.05 (6.8–9.4)

8.4 (6.9–9.97)

0.12

MCH

28 (26.4–29.5)

27.3 (25.6–28.8)

0.013

MCHC

32.9 (32–33.7)

32.65 (31.42–33.22)

0.008

RDW-CV

13.7 (13.1–14.7)

14.25 (13.2–15.25)

0.042

CRP

6 (2–18)

10 (4–23)

0.054

NLR

2.31 (1.7–3.52)

2.64 (2.04–3.71)

0.15

MLR

0.25 (0.19–0.36)

0.28 (0.23–0.38)

0.19

IQR: interquartile range, MCH: mean cell hemoglobin, MCHC: mean cell hemoglobin concentration, NLR:
neutrophil-lymphocyte ratio, MLR: monocyte-lymphocyte ratio, P: significance level, RDW-CV: red cell
distribution width coefficient of variation, CRP: C reactive protein.

3.3. Inflammatory markers as predictors of secondary EN
NLR, MLR, PLR, WBC, sedimentation, CRP, PDW, and
RDW-CV were all increased in secondary EN patients
compared to idiopathic EN. We performed receiver
operating characteristic (ROC) curve analysis to identify
predictors of secondary EN and their optimal cut-offs.
The strongest predictor of secondary EN was NLR with

an area under the curve (AUC) of 0.875 (Figure 4). The
optimum cut-off for NLR was 2.11. NLR > 2.11 predicted
secondary EN with 83.8% sensitivity and 80.5% specificity
(P < 0.001). AUC, cut-offs, sensitivity, specificity, and
statistical significance of MLR, PLR, WBC, sedimentation,
CRP, PDW, and RDW-CV in predicting secondary EN are
summarized in Table 8.
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Table 5. Laboratory features of EN patients compared to control group.

Age (IQR)

EN patients
(n = 395)

Control group
(n = 395)

P value

39 (30–50)

40 (27–52)

0.45

Sex (male/female)

79/316

79/316

1

WBC (109/L) (IQR)

8.1 (6.87–9.42)

7.2 (6.1–8.4)

<0.001

Neutrophil (109/L) (IQR)

5.05 (3.9–6.5)

3.8 (3.2–4.7)

<0.001

Lymphocyte (10 /L) (IQR)

2.1 (1.6–2.52)

2.5 (2.1–3)

<0.001

Monocyte (109/L) (IQR)

0.6 (0.4–0.7)

0.5 (0.4–0.7)

0.02

Hemoglobin (g/dL) (IQR)

13.1 (12.1–14.2)

13.8 (12.9–14.8)

<0.001

MCV (fL) (IQR)

85 (81.27–87.92)

86.3 (83.6–89.1)

<0.001

MCH (pg) (IQR)

27.9 (26.3–29.4)

28.6 (27.2–29.5)

<0.001

MCHC (g/dL) (IQR)

32.8 (31.9–33.6)

32.9 (32.1–33.8)

0.18

9

Platelet (10 /L) (IQR)

280.5 (232.7–332.5)

274 (236–320)

0.23

MPV (fL) (IQR)

10 (8–11)

11 (10–11)

<0.001

PDW (%) (IQR)

16 (13–16.6)

12.3 (10.9–13.72)

<0.001

RDW-CV (%) (IQR)

13.8 (13.1–14.8)

13.1 (12.6–13.7)

<0.001

NLR (IQR)

2.38 (1.73–3.58)

1.55 (1.23–1.8)

<0.001

MLR (IQR)

0.26 (0.2–0.36)

0.21 (0.17–0.25)

<0.001

PLR (IQR)

136.27 (103.47–169.51)

107.6 (87.77–132.22)

<0.001

9

N: sample size, MCV: mean corpuscular volume, MCH: mean cell hemoglobin, MCHC: mean cell
hemoglobin concentration, MPV: mean platelet volume, NLR: neutrophil-lymphocyte ratio, MLR:
monocyte-lymphocyte ratio, PLR: platelet-lymphocyte ratio, WBC: white blood cell, P: significance level,
PDW: platelet distribution width, RDW-CV: red cell distribution width coefficient of variation.

3.4. Multivariate logistic regression analysis
Separate multivariate logistic regression analysis was
performed to identify risk factors for EN, secondary EN,
and recurrent EN. The values of NLR > 2.11 and RDWCV > 13.65 increased the risk of EN (relative risks 17.88
and 3, respectively). Among EN patients, NLR > 2.11,
recurrent EN, RDW-CV > 13.65, and CRP > 5.5 were risk
factors for secondary EN (relative risks 17.16, 3.55, 2.69,
and 2, respectively) (Table 9). Secondary EN, age > 40, and
MCHC < 33 were risk factors for recurrent EN (relative
risks 3.68, 2.23, and 2.39, respectively).
4. Discussion
EN is an inflammatory disorder of subcutaneous tissue
characterized by erythematous, tender subcutaneous
nodules predominantly affecting lower extremities.
Although many etiologic factors such as infections,
systemic disease, and drugs have been identified as causes
of EN, many cases of EN still remain idiopathic.
To our knowledge, there is no definitive clinical or
laboratory data that can distinguish idiopathic EN from
secondary EN. Our purpose in this study was to compare
NLR levels in EN patients versus controls and evaluate
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NLR changes in the presence of a precipitating cause
of EN. NLR was elevated in EN patients compared to
controls. Among EN patients, NLR was also elevated in
patients with secondary EN compared to idiopathic EN.
Similar to figures reported in the literature, 34.7%
of EN was idiopathic in our series (5,21,22). Infections
(especially upper respiratory tract and urinary tract) and
systemic diseases (especially rheumatologic diseases) were
the leading causes of secondary EN. Although most of
the patients with infection and systemic disease, which
were listed as precipitating factors in patients’ files, were
symptomatic, 41.5% of 82 EN patients with URTI were
diagnosed by screening tests and microbiological workup
after admission. Asymptomatic URTI, such as tonsillitis
or pharyngitis, was diagnosed in 7% of 129 EN patients
evaluated by Cribier et al. (6). The ratio of asymptomatic/
symptomatic infection was much higher in our patients
with UTI, the second most common infection among
EN patients. Forty-six of 48 patients with UTI (95.8%)
were diagnosed after urinary analysis and culture. These
findings show us that patients with infections may be
asymptomatic or may be showing mild symptoms, so
laboratory and microbiological tests are essential to

HAYRAN et al. / Turk J Med Sci
Table 6. Laboratory features of secondary EN patients compared to idiopathic EN.

Age (IQR)

Secondary EN
(n = 258)

Idiopathic EN
(n = 137)

P value

38 (29.7–49)

42 (31.5–53)

0.062

Sex (male/female)

52/206

27/110

0.91

WBC (109/L) (IQR)

8.5 (7.1–10.35)

7.3 (6.15–8.45)

<0.001

Neutrophil (109/L) (IQR)

5.6 (4.6–7.3)

3.9 (3.4–4.9)

<0.001

Lymphocyte (10 /L) (IQR)

1.9 (1.55–2.4)

2.4 (2–2.8)

<0.001

Monocyte (109/L) (IQR)

0.6 (0.5–0.8)

0.5 (0.4–0.6)

0.01

Hemoglobin (g/dL) (IQR)

12.8 (11.85–13.8)

13.6 (12.5–14.4)

<0.001

MCV (fL) (IQR)

84.8 (80.4–87.55)

85.5 (82.35–88.4)

0.034

MCH (pg) (IQR)

27.6 (26–29.2)

28.3 (26.7–29.7)

0.011

MCHC (g/dL) (IQR)

32.7 (31.8–33.5)

33 (32.1–33.85)

0.050

9

Platelet (10 /L) (IQR)

284 (237.5–345)

275 (226.5–308.5)

0.012

MPV (fL) (IQR)

9 (8–10)

10 (9–11)

0.006

PDW (%) (IQR)

16.2 (13.2–16.7)

14.65 (12.62–16.5)

0.027

RDW-CV (%) (IQR)

13.9 (13.2–15)

13.5 (13.1–14.5)

0.013

NLR (IQR)

2.88 (2.31–4.07)

1.66 (1.39–1.95)

<0.001

MLR (IQR)

0.3 (0.22–0.4)

0.21 (0.17–0.27)

<0.001

PLR (IQR)

152.38 (120.8–191.34)

109 (88.96–138.02)

<0.001

Sedimentation (mm/h) (IQR)

24 (12–43)

14 (7–22.5)

<0.001

CRP (mg/L) (IQR)

10 (3–31)

4 (1–8)

<0.001

9

N: sample size, MCV: mean corpuscular volume, MCH: mean cell hemoglobin, MCHC: mean cell hemoglobin
concentration, MPV: mean platelet volume, NLR: neutrophil-lymphocyte ratio, MLR: monocyte-lymphocyte
ratio, PLR: platelet-lymphocyte ratio, WBC: white blood cell, P: significance level; PDW: platelet distribution
width, RDW-CV: red cell distribution width coefficient of variation.

Figure 2. Median NLR was significantly higher in EN patients. *** P < 0.001.
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Figure 3. NLR of secondary EN patients was higher than that of idiopathic EN and control group. * P < 0.01, *** P < 0.001.
Table 7. Correlations between NLR, MLR, PLR and conventional inflammatory markers.
NLR
r

MLR
P

r

PLR
P

r

P

WBC

0.38

<0.001

0.24

<0.001

–0.07

0.051

MPV

–0.25

<0.001

–0.14

<0.001

–0.28

< 0.001

PDW

0.27

<0.001

0.09

0.01

0.011

0.76

RDW-CV

0.17

<0.001

0.08

0.035

0.16

<0.001

Sedimentation

0.33

<0.001

0.19

<0.001

0.37

<0.001

CRP

0.44

<0.001

0.36

<0.001

0.31

<0.001

ASO

0.19

0.011

0.18

0.02

0.21

0.01

NLR

-

-

0.63

<0.001

0.59

<0.001

MLR

0.63

<0.001

-

-

0.44

<0.001

PLR

0.59

<0.001

0.44

<0.001

-

-

MPV: mean platelet volume, NLR: neutrophil-lymphocyte ratio, MLR: monocyte-lymphocyte ratio, PLR:
platelet-lymphocyte ratio, WBC: white blood cell, P: significance level, PDW: platelet distribution width, RDWCV: red cell distribution width coefficient of variation, CRP: C reactive protein, ASO: antistreptolysin O.

identify a possible infection as the etiological factor. The
higher NLR shown in asymptomatic EN patients with
infections makes this marker a candidate to prioritize the
patients to be screened.
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Systemic diseases were the second most common
etiological factor of EN, and rheumatologic diseases were
the most common systemic disease. Twelve of 71 patients
(16.9%) had a history of rheumatologic disease, but in 59
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Figure 4. Receiver operating characteristic (ROC) curve analysis to identify
predictors of secondary EN.
Table 8. AUC, cut-offs, sensitivity, specificity, and statistical significance of MLR, PLR, WBC, sedimentation, CRP,
PDW, and RDW-CV in predicting secondary EN.
Cut-off value

Sensitivity

Specificity

P value

AUC

WBC

7.95

64.4

64.6

<0.001

0.686

PDW

15.75

59.9

55.8

0.029

0.573

RDW-CV

13.65

60.8

52.2

0.068

0.561

Sedimentation

16.5

65.3

60.2

<0.001

0.683

CRP

5.5

67.1

60.2

<0.001

0.703

NLR

2.11

83.8

80.5

<0.001

0.875

MLR

0.24

68.5

62.8

<0.001

0.715

PLR

127.59

68

64.6

<0.001

0.744

NLR: neutrophil-lymphocyte ratio, MLR: monocyte-lymphocyte ratio, PLR: platelet-lymphocyte ratio, WBC: white
blood cell, PDW: platelet distribution width, RDW-CV: red cell distribution width coefficient of variation, CRP: C
reactive protein.

patients (83.1%) the rheumatologic disease was diagnosed
after EN. Similar to infections, patients with systemic
diseases, both previously diagnosed and undiagnosed,
had a higher NLR compared to patients with idiopathic

EN. NLR may be a good candidate for a screening test for
undiagnosed or asymptomatic infections and systemic
diseases, and patients with high NLR should be investigated
more carefully for an undiagnosed precipitating factor.
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Table 9. Multivariate logistic regression analysis identifying risk factors for EN
and secondary EN.
RR (95% CI)

P value

Risk factor for EN
NLR (>2.11)

17.88 (11.7–27.33)

<0.001

RDW-CV (>13.65)

3.06 (2.25–4.17)

<0.001

17.16 (9.33–31.55)

<0.001

Risk factors for secondary EN
NLR (>2.11)
Recurrent EN

3.55 (1.49–8.49)

0.004

RDW-CV (>13.65)

2.69 (1.5–4.84)

0.001

CRP (>5.5)

2 (1.15–3.65)

0.014

Risk factors for recurrent EN
Secondary EN

3.68 (1.78–7.61)

<0.001

Age (>40)

2.23 (1.27–3.94)

0.006

MCHC (<33)

2.39 (1.29–4.45)

0.006

NLR: neutrophil-lymphocyte ratio, RDW-CV: red cell distribution width
coefficient of variation, CRP: C reactive protein, MCHC: mean cell hemoglobin
concentration.

Our study showed that NLR increased in both idiopathic
EN and secondary EN, but the increase in secondary EN
was more prominent and significant. Systemic diseases
and infection were the most frequent causes of secondary
EN; previous studies revealed that NLR increases as an
inflammatory marker in many systemic diseases (10–17).
In our study, the more prominent and significant increase
in NLR may be attributed to the secondary systemic and
infectious diseases in EN. That’s why a more prominent
increase in NLR should alert the physician to an underlying
precipitating disease.
Recurrence was identified in 16.2 % of EN patients.
Advanced age, identification of an etiological factor,
and low MCHC increased the risk of recurrent EN in
multivariate logistic regression analysis. Papagrigoraki et
al. also investigated the characteristics of relapsing EN.
An etiological factor such as infection, drugs, systemic
diseases, or pregnancy was identified in 75.8% of EN
patients. Although infections, drugs, and pregnancy
were more common in relapsing EN, multiple regression
analysis showed that only drugs increase the risk of EN
relapses (9). In our study, drug history was positive in
4.3% of EN patients and OCs was the most common
drug, similar to other series in the literature (1,4,5,8,23).
Identification and removal of the causes, especially drugs,
are important for treatment of EN as well as for limiting
the recurrence.
Secondary EN was identified in 65.3% of patients.
Patients with secondary EN were younger and had higher
inflammatory markers than patients with idiopathic
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EN. After multivariate regression analysis, our results
showed that high NLR (> 2.11), RDW-CV (> 13.65),
CRP (> 5.5), and recurrence of EN predict secondary EN.
Previous studies aimed to predict EN with an underlying
precipitating factor, but none of the clinical or laboratory
features investigated could predict secondary EN with
high sensitivity and specificity. Dogan et al. investigated
clinical and laboratory features of EN patients with an
underlying systemic disease (24). The study showed that
patients with complicated EN had higher platelet levels,
and EN lesions were located at nonclassic localizations.
Kisacik et al. reported that patients with secondary EN
were younger and had higher sedimentation and CRP
levels (25). Ozbagcivan et al. also investigated etiological
factors in EN and they divided EN patients into 3 groups
as idiopathic, infectious, and noninfectious EN (26).
They compared both clinical and laboratory features of
idiopathic, infectious, and noninfectious EN. Patients with
infectious EN had fewer EN lesions, lower percentage of
systemic symptoms, and higher ESR compared to those
with noninfectious and idiopathic EN. On the other hand,
patients with noninfectious EN had higher AST levels
(26). ESR and CRP are well known inflammatory markers
that are used in daily practice to identify infections and
systemic diseases in EN patients. Our study showed that
NLR was more sensitive and specific then previously
studied ERS and CRP levels in identifying secondary EN.
Although all 3 studies identified features of secondary EN,
the predictive value of these features for secondary EN was
not quantified.
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To the best of our knowledge this is the first study
investigating NLR in EN patients. NLR was investigated
as a novel inflammatory marker in many dermatological
diseases. In psoriasis, NLR was increased compared to
controls, decreased with treatment, and correlated with
disease severity and conventional inflammatory markers
(14,27,28). High NLR may also be used as a predictor of
arthritis in psoriatic patients (29). NLR also increases in
other dermatological diseases such as Behçet’s disease,
liken planus, Hidradenitis Supurativa, vitiligo, and
atopic dermatitis. Like in psoriasis, NLR correlates with
disease severity and other inflammatory markers in these
inflammatory skin diseases (15,30–34).
Our study revealed that with a cutoff point of 2.11,
NLR predicts EN among all participants and secondary EN
among all EN patients with high sensitivity and specificity.
The diagnostic value of NLR has been previously investigated
in pneumonia and brucellosis. Yoon et al. showed that NLR
with a cutoff point of 7 may distinguish between bacterial
pneumonia and tuberculosis, and NLR < 7 is predictive
for tuberculosis (35). Diagnosis of EN is based on clinical
or histopathological features and NLR is an inflammatory
marker which may increase in all inflammatory and
neoplastic diseases. Using NLR for diagnosis of EN may

therefore not be practical. However, our findings strongly
suggest that selecting out secondary EN among clinically or
histopathologically diagnosed EN patients with this cheap
and easy marker is possible.
This study was designed as a retrospective cross
sectional study. Although we were able to retrospectively
evaluate the medical records of a large group of EN patients,
information on the clinical course of the disease was limited
and we relied on existing information in patient charts.
This precluded us from investigating the relationship
between additional clinical characteristics such as atypical
presentation and lesion count in predicting secondary EN.
Identification and elimination of a possible underlying
cause of EN is a very important step in treatment and
not letting the precipitating factor go undiagnosed is
important to limit recurrence. Medical history and physical
examination are essential in identifying the cause, but in
patients with previously undiagnosed comorbidities or
asymptomatic infections additional laboratory work-up
may be required. NLR is a cheap and easy marker that
can be used to predict secondary EN with high sensitivity
and specificity. High NLR can alert the physician against
secondary EN, where extensive screening for a precipitating
factor should not be neglected.
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